We systematically analyzed cross-reactivity and potential efficacy of current FDA-approved human ICIs in vitro using canine cell lines and PBMCs from healthy donors as well as cancer patient-dogs with a particular focus on the PD-1/PD-L1 axis. Here, CD274 is linked to cancer.